Phreesia, Inc. (NYSE:PHR) General Counsel Sells $180,158.88 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 6,556 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $180,158.88. Following the completion of the sale, the general counsel now directly owns 152,361 shares of the company’s stock, valued at approximately $4,186,880.28. This represents a 4.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Phreesia Stock Performance

NYSE:PHR traded down $0.49 during trading hours on Wednesday, reaching $28.81. The company had a trading volume of 384,950 shares, compared to its average volume of 392,842. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -19.60 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm’s 50 day moving average price is $24.57 and its 200-day moving average price is $23.20. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.90.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same period in the previous year, the company posted ($0.58) EPS. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of PHR. Champlain Investment Partners LLC boosted its position in shares of Phreesia by 4.1% in the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after purchasing an additional 97,847 shares during the period. Franklin Resources Inc. boosted its holdings in Phreesia by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after buying an additional 42,973 shares during the period. State Street Corp boosted its holdings in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after buying an additional 88,517 shares during the period. Geode Capital Management LLC raised its holdings in Phreesia by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares during the period. Finally, TimesSquare Capital Management LLC lifted its position in shares of Phreesia by 2.3% in the third quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company’s stock valued at $19,791,000 after acquiring an additional 19,395 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PHR shares. Truist Financial lifted their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Robert W. Baird lowered their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a report on Friday, January 10th. Finally, JMP Securities reiterated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.15.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.